Romiplostim for treatment-resistant aplastic anemia
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a drug called romiplostim (Nplate) for patients whose aplastic anemia—a rare blood disorder where the bone marrow stops making enough blood cells—didn't improve after cancer treatment and hasn't responded to other medications. The drug may help your bone marrow produce more blood cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Aplastic anemia caused by chemotherapy or radiation that didn't get better after at least 3 months of treatment with cyclosporine or similar drugs
- At least one blood count that is dangerously low (hemoglobin, platelets, or neutrophils)
- Liver and kidney function tests close to normal range
- No active uncontrolled infection
- Able to perform light daily activities (ECOG score 0–2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining a drug called romiplostim (a bone marrow stimulant) with standard immunosuppressive therapy as a first treatment for severe aplastic anemia. It aims to improve blood cell counts and reduce the need for transfusions.
This trial tests adding romiplostim to standard care for severe aplastic anemia (a condition where the bone marrow doesn't make enough blood cells) in patients aged 2 to 21. It aims to see if this combination improves blood cell counts in those newly diagnosed or whose disease has come back or not responded to prior treatment.
This study tests a drug called romiplostim to see if it can help people with non-severe aplastic anemia (NSAA) who still need regular blood transfusions even after standard treatments. Romiplostim works by stimulating your body to make more blood cells, which may reduce your need for transfusions.
This trial tests a new drug called ropustine to see if it can help people with aplastic anemia that hasn't responded to other treatments. The study is at one hospital and will monitor how well your blood counts and symptoms improve.
This trial tests whether adding romiplostim (a drug that helps make platelets) to standard immunosuppressive therapy works better than standard therapy alone for people with severe aplastic anemia who have not been treated before. It aims to see if the combination can improve blood counts.
This trial tests if romiplostim, a drug that helps the body make platelets, can speed up platelet recovery after a special type of stem cell transplant from a half-matched donor. It may help reduce bleeding risk during the recovery period.
Hear when a new Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.